Centene Stock (CNC)

XNYS Alert Compare

Health Care · Fundamental analysis

Centene's revenue has grown by 11.9% a year over the last 5 years – faster than the median of the Health Care sector (+8.5%). The last fiscal year ended with a net loss (net margin −3.4%, sector median 13.9%). The 52-week high is 22.4% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

1 strength · 3 weaknesses · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 0 of 7 criteria with data met · 1 without data
  • Growth 5 of 7 criteria with data met
  • Dividend 0 of 1 criteria with data met · 6 without data
  • Financial strength 5 of 6 criteria with data met
Chart position more than 10% above – position relative to the 200-day line

Strengths well above the threshold

  • Revenue growth 5 years +11.9% per year Threshold: above 5% per year · Distance +6.9 pp · Sector median +7.8% per year (60 stocks) · Fiscal year to Dec 31, 2025

Weaknesses well below the threshold

  • Net margin −3.4% Threshold: above 10% · Distance −13.4 pp · Sector median 12.9% (63 stocks) · Fiscal year to Dec 31, 2025
  • Return on equity −33.4% Threshold: above 15% · Distance −48.4 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 31, 2025
  • Free cash flow margin 2.2% Threshold: above 10% · Distance −7.8 pp · Sector median 14.5% (61 stocks) · Fiscal year to Dec 31, 2025

On the radar

  • Position relative to the 200-day line: more than 10% above (as of Nov 20, 2026)
  • Equity ratio 26.0% – Threshold: above 30%, distance −4.0 pp (Fiscal year to Dec 31, 2025)

What we do not know

  • Data missing: 1 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 31, 2025).
    • Free cash flow positive in each of the last 3 fiscal years

Not applicable

  • Pays no dividend – the dividend criteria do not apply (Fiscal year to Dec 31, 2025).

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Centene is a health insurer from St. Louis that specializes in government-funded programs. It covers many members in the Medicaid program for people with low incomes, in marketplace plans under the “Obamacare” law and in Medicare. As of Oct 11, 2026

Fact sheet (from the annual report) Health insurance and health plans · St Louis, USA

According to the company, Centene is a managed care company focused on underserved populations and is incorporated in Delaware. In 2025 Centene operated in the segments Medicaid, Medicare, commercial insurance and other. The Medicaid segment includes programs for low-income families with children, for elderly, blind or disabled people and for long-term care, among others. The Medicare segment includes Medicare Advantage, special plans for people eligible for both programs, stand-alone prescription drug plans and supplemental insurance. The commercial segment offers policies through the Health Insurance Marketplace as well as individual and group insurance. Centene offers Medicare Advantage mainly under the Wellcare brand.

Automatically summarized from SEC annual report (10-K, filed Feb 17, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

What the methods say about Centene

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today −2.7%
  • 7 days −10.5%
  • 30 days −9.2%
  • 1 year +83.2%
Day range (last trading day)
−0.8%Price at 12% of the range+5.7%
52-week range
−50.4%Price at 69% of the range+22.4%
Distance from the all-time high
−35.3%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles up
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • higher highs and higher lows

    Price below the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and weaker than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
weaker
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX below 20 – hardly any trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility high Typical daily range (ATR 14) above 4% of the price – high.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran weaker.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 8 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
8 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
4 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 7 of 10 years
  • February: higher in 4 of 10 years
  • March: higher in 7 of 10 years
  • April: higher in 5 of 10 years
  • May: higher in 5 of 10 years
  • June: higher in 5 of 10 years
  • July: higher in 5 of 10 years
  • August: higher in 5 of 10 years
  • September: higher in 3 of 10 years
  • October: higher in 6 of 10 years
  • November (current month): higher in 8 of 10 years
  • December: higher in 5 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January7 of 10
February4 of 10
March7 of 10
April5 of 10
May5 of 10
June5 of 10
July5 of 10
August5 of 10
September3 of 10
October6 of 10
November ●8 of 10
December5 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

Centene Corporation · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 17, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 7
criteria with data met
Revenue per year (5 y)
+11.9%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
0 of 7
criteria with data met
Net margin
−3.4%
Return on equity
−33.4%

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
up
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 0 of 7 met · 1 without data

  • not met: Gross margin above 40% 7.3%
  • not met: Operating margin above 15% −3.9%
  • not met: Net margin above 10% −3.4%
  • not met: Return on equity above 15% −33.4%
  • not met: Free cash flow margin above 10% 2.2%
  • not met: Profit in each of the last 5 fiscal years 4 of 5
  • no data: Free cash flow positive in each of the last 3 fiscal years not stated in the SEC filings
  • not met: Equity ratio above 30% 26.0%
Gross margin

7.3% Fiscal year 2025

Rank 4 of 100: higher than 4% of 370 peers (All). weak.

Rank 7 of 100: higher than 7% of 49 peers (Sector). weak.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

−3.9% Fiscal year 2025

Rank 12 of 100: higher than 12% of 470 peers (All). weak.

Rank 8 of 100: higher than 8% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

−3.4% Fiscal year 2025

Rank 11 of 100: higher than 11% of 584 peers (All). weak.

Rank 10 of 100: higher than 10% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

−33.4% Fiscal year 2025

Rank 5 of 100: higher than 5% of 544 peers (All). weak.

Rank 3 of 100: higher than 3% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

−8.7% Fiscal year 2025 (total assets at year end)

Rank 6 of 100: higher than 6% of 594 peers (All). weak.

Rank 7 of 100: higher than 7% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

26.0% Fiscal year 2025

Rank 33 of 100: higher than 33% of 595 peers (All). medium.

Rank 23 of 100: higher than 23% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

2.2% Fiscal year 2025

Rank 21 of 100: higher than 21% of 465 peers (All). weak.

Rank 19 of 100: higher than 19% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

4.3B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +10.5%
  • met: Over 5 years, revenue grew by more than 5% per year +11.9%
  • met: Over 10 years, revenue grew by more than 5% per year +23.9%
  • not met: Over 3 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Over 5 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +19.4%
Revenue growth 3 years

+10.5% per year

Rank 69 of 100: higher than 69% of 578 peers (All). strong.

Rank 77 of 100: higher than 77% of 62 peers (Sector). strong.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+11.9% per year

Rank 64 of 100: higher than 64% of 549 peers (All). medium.

Rank 78 of 100: higher than 78% of 60 peers (Sector). strong.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+23.9% per year

Rank 93 of 100: higher than 93% of 412 peers (All). strong.

Rank 89 of 100: higher than 89% of 50 peers (Sector). strong.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 4 of 9
  • met: Long-term debt no higher than equity 0.88
  • met: Current assets cover current liabilities 1.10
  • met: Positive equity 20.0B USD
  • met: In 5 years, share count up by at most 5% −14.9%
  • met: Free cash flow positive in the last fiscal year 4.3B USD
Piotroski F-Score

4 of 9 Fiscal year 2025

Rank 8 of 100: higher than 8% of 310 peers (All). weak.

Rank 5 of 100: higher than 5% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.88 at fiscal year end

Rank 37 of 100: lower than 37% of 486 peers (All). medium.

Rank 23 of 100: lower than 23% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.10 at fiscal year end

Rank 35 of 100: higher than 35% of 513 peers (All). medium.

Rank 20 of 100: higher than 20% of 63 peers (Sector). weak.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−14.9% in 5 years

Rank 85 of 100: lower than 85% of 507 peers (All). strong.

Rank 86 of 100: lower than 86% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • not met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+11.9% per year), at least as fast as the sector median.
  • Light red: Loss in the last fiscal year.
  • Light yellow: Debt higher than usual in the sector.
  • Light yellow: Profit in 9 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 40.6B USD · Net income 562.0M USD · Net margin 1.4%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 48.4B USD · Net income 828.0M USD · Net margin 1.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 60.1B USD · Net income 900.0M USD · Net margin 1.5%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 74.6B USD · Net income 1.3B USD · Net margin 1.8%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 111.1B USD · Net income 1.8B USD · Net margin 1.6%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 126.0B USD · Net income 1.3B USD · Net margin 1.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 144.5B USD · Net income 1.2B USD · Net margin 0.8%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 154.0B USD · Net income 2.7B USD · Net margin 1.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 163.1B USD · Net income 3.3B USD · Net margin 2.0%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 194.8B USD · Net income −6.7B USD · Net margin −3.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 194.8B USD · Net income −6.7B USD · Net margin −3.4%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +1.9% vs. the same quarter a year earlier; grown for at least 16 quarters in a row.

Revenue 12 months vs. prior 12
+9.7%
12 months: 203.9B USD · Fiscal year 2025: +19.4%
Net margin 12 months
0.7%
Fiscal year 2025: −3.4%
Free cash flow margin 12 months
1.9%
Fiscal year 2025: 2.2%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 194.8B USD + year to date to Sep 30, 2026 154.2B USD − same period a year earlier to Sep 30, 2025 145.1B USD = 203.9B USD
  • Net income: fiscal year to Dec 31, 2025 −6.7B USD + year to date to Sep 30, 2026 2.6B USD − same period a year earlier to Sep 30, 2025 −5.6B USD = 1.5B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 5.1B USD + year to date to Sep 30, 2026 4.3B USD − same period a year earlier to Sep 30, 2025 4.7B USD = 4.7B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 767.0M USD + year to date to Sep 30, 2026 568.0M USD − same period a year earlier to Sep 30, 2025 554.0M USD = 781.0M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 2650.6B+1.9%−71.0M−0.1%
Apr–Jun 2653.6B+9.9%1.1B2.0%
Jan–Mar 2649.9B+7.1%1.5B3.1%
Oct–Dec 25*49.7B+21.9%−1.1B−2.2%
Jul–Sep 2549.7B+18.2%−6.6B−13.3%
Apr–Jun 2548.7B+22.4%−253.0M−0.5%
Jan–Mar 2546.6B+15.4%1.3B2.8%
Oct–Dec 24*40.8B+3.4%283.0M0.7%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Oct 27, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

There was no profit in fiscal year 2025; operating income does not cover interest.

Cash flow ÷ profit
–
no profit in fiscal year 2025
Interest coverage
negative
operating income negative · 3 years: negative
Tax rate
–
no profit before tax · 3 years: 160.7%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 5.1B USD ÷ group profit incl. minority interests −6.7B USD = no ratio (no profit)
  • Operating income −7.6B USD ÷ Interest expense 678.0M USD = negative
  • Taxes −51.0M USD ÷ profit before tax −6.7B USD = no rate (no profit before tax)
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
2025–negative–
2024–4.5x22.6%
20232.98x4.0x25.0%
20225.21x2.0x38.7%
20213.15x2.7x26.3%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years one loss year and no year with lower revenue.

Loss years
1 of 10
net income below zero
Years with lower revenue
0 of 10
revenue below the prior year
Net margin range
5.5 percentage points
from −3.4% to 2.0%
Net margin by fiscal year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+19.4%−3.4%
2024+5.9%2.0%
2023+6.5%1.8%
2022+14.7%0.8%
2021+13.4%1.1%
2020+48.9%1.6%
2019+24.2%1.8%
2018+24.3%1.5%
2017+19.1%1.7%
2016+78.4%1.4%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 7.3 USD gross profit remained.

Operating loss: −3.9% of revenue

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue194.8B USD100.0%
Gross profit14.2B USD7.3%
Cost of revenue180.6B USD92.7%
Operating expenses21.8B USD11.2%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 2.8% to −3.9%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin not available · Operating margin 3.1% · Net margin 1.4%
  2. Fiscal year 2017: Gross margin not available · Operating margin 2.5% · Net margin 1.7%
  3. Fiscal year 2018: Gross margin not available · Operating margin 2.4% · Net margin 1.5%
  4. Fiscal year 2019: Gross margin not available · Operating margin 2.4% · Net margin 1.8%
  5. Fiscal year 2020: Gross margin not available · Operating margin 2.8% · Net margin 1.6%
  6. Fiscal year 2021: Gross margin 11.5% · Operating margin 1.4% · Net margin 1.1%
  7. Fiscal year 2022: Gross margin 11.7% · Operating margin 0.9% · Net margin 0.8%
  8. Fiscal year 2023: Gross margin 11.5% · Operating margin 1.9% · Net margin 1.8%
  9. Fiscal year 2024: Gross margin 10.5% · Operating margin 1.9% · Net margin 2.0%
  10. Fiscal year 2025: Gross margin 7.3% · Operating margin −3.9% · Net margin −3.4%

Returns

Return on equity fell in 5 years from 7.0% to −33.4%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 9.5% · Return on assets 2.8%
  2. Fiscal year 2017: Return on equity 12.1% · Return on assets 3.8%
  3. Fiscal year 2018: Return on equity 8.2% · Return on assets 2.9%
  4. Fiscal year 2019: Return on equity 10.5% · Return on assets 3.2%
  5. Fiscal year 2020: Return on equity 7.0% · Return on assets 2.6%
  6. Fiscal year 2021: Return on equity 5.0% · Return on assets 1.7%
  7. Fiscal year 2022: Return on equity 5.0% · Return on assets 1.6%
  8. Fiscal year 2023: Return on equity 10.5% · Return on assets 3.2%
  9. Fiscal year 2024: Return on equity 12.5% · Return on assets 4.0%
  10. Fiscal year 2025: Return on equity −33.4% · Return on assets −8.7%

Equity and long-term debt

The equity ratio fell in 5 years from 37.5% to 26.0%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 5.9B USD · Long-term debt 4.8B USD
  2. Fiscal year 2017: Equity 6.9B USD · Long-term debt 4.8B USD
  3. Fiscal year 2018: Equity 10.9B USD · Long-term debt 6.9B USD
  4. Fiscal year 2019: Equity 12.6B USD · Long-term debt 13.9B USD
  5. Fiscal year 2020: Equity 25.8B USD · Long-term debt 16.9B USD
  6. Fiscal year 2021: Equity 26.8B USD · Long-term debt 19.0B USD
  7. Fiscal year 2022: Equity 24.1B USD · Long-term debt 18.2B USD
  8. Fiscal year 2023: Equity 25.8B USD · Long-term debt 18.0B USD
  9. Fiscal year 2024: Equity 26.4B USD · Long-term debt 18.6B USD
  10. Fiscal year 2025: Equity 20.0B USD · Long-term debt 17.5B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (1.10).

Current ratio
  1. Fiscal year 2016: Current ratio 0.97
  2. Fiscal year 2017: Current ratio 0.93
  3. Fiscal year 2018: Current ratio 1.00
  4. Fiscal year 2019: Current ratio 1.57
  5. Fiscal year 2020: Current ratio 1.08
  6. Fiscal year 2021: Current ratio 1.11
  7. Fiscal year 2022: Current ratio 1.06
  8. Fiscal year 2023: Current ratio 1.11
  9. Fiscal year 2024: Current ratio 1.11
  10. Fiscal year 2025: Current ratio 1.10

Cash flow

Free cash flow fell in 5 years from 4.6B USD to 4.3B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 1.9B USD · Capital expenditure 306.0M USD · Free cash flow 1.5B USD
  2. Fiscal year 2017: Operating cash flow 1.5B USD · Capital expenditure 422.0M USD · Free cash flow 1.1B USD
  3. Fiscal year 2018: Operating cash flow 1.2B USD · Capital expenditure 675.0M USD · Free cash flow 559.0M USD
  4. Fiscal year 2019: Operating cash flow 1.5B USD · Capital expenditure 730.0M USD · Free cash flow 753.0M USD
  5. Fiscal year 2020: Operating cash flow 5.5B USD · Capital expenditure 869.0M USD · Free cash flow 4.6B USD
  6. Fiscal year 2021: Operating cash flow 4.2B USD · Capital expenditure 910.0M USD · Free cash flow 3.3B USD
  7. Fiscal year 2022: Operating cash flow 6.3B USD · Capital expenditure 1.0B USD · Free cash flow 5.3B USD
  8. Fiscal year 2023: Operating cash flow 8.1B USD · Capital expenditure 799.0M USD · Free cash flow 7.3B USD
  9. Fiscal year 2024: Operating cash flow not available · Capital expenditure 644.0M USD · Free cash flow not available
  10. Fiscal year 2025: Operating cash flow 5.1B USD · Capital expenditure 767.0M USD · Free cash flow 4.3B USD

Share count

The share count fell in 5 years by 14.9% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 328.0M
  2. Fiscal year 2017: Diluted share count 353.4M
  3. Fiscal year 2018: Diluted share count 398.5M
  4. Fiscal year 2019: Diluted share count 420.4M
  5. Fiscal year 2020: Diluted share count 579.1M
  6. Fiscal year 2021: Diluted share count 590.5M
  7. Fiscal year 2022: Diluted share count 582.0M
  8. Fiscal year 2023: Diluted share count 545.7M
  9. Fiscal year 2024: Diluted share count 523.7M
  10. Fiscal year 2025: Diluted share count 493.1M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

No annual figures for this stock: Dividend per share, Payout ratio (earnings), Payout ratio (free cash flow).

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (5 years)
8.6B USD 100% through repurchases
Share count over 5 years
−14.9% fewer shares – each share is a larger stake

What goes back to shareholders

Over 5 years, 8.6B USD went back to shareholders, 100% of it through share repurchases. This was offset by new shares issued for 232.0M USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 63.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 1.5B USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 65.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 1.1B USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 71.0M USD · New shares issued (including employee plans) 2.8B USD · Free cash flow 559.0M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 75.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 753.0M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 626.0M USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 4.6B USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 297.0M USD · New shares issued (including employee plans) 35.0M USD · Free cash flow 3.3B USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 3.1B USD · New shares issued (including employee plans) 70.0M USD · Free cash flow 5.3B USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 1.6B USD · New shares issued (including employee plans) 44.0M USD · Free cash flow 7.3B USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 3.1B USD · New shares issued (including employee plans) 46.0M USD · Free cash flow not available
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 475.0M USD · New shares issued (including employee plans) 37.0M USD · Free cash flow 4.3B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Centene Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison CNC, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
UNH UnitedHealth Group 447.6B USD +11.7%–4.2%2.7%12.0%32.3%3.6%7/9
MCK McKesson Corporation 403.4B USD +11.1%3.6%1.5%1.2%–−2.6%1.4%6/9
CVS CVS Health 402.1B USD +8.4%–1.2%0.4%2.4%29.7%1.9%7/9
CI Cigna 274.9B USD +11.4%–3.3%2.2%14.3%26.4%–7/9
ELV Elevance Health 199.1B USD +10.3%–3.6%2.8%12.9%36.1%1.6%7/9
CNC Centene Corporation this stock 194.8B USD +11.9%7.3%−3.9%−3.4%−33.4%26.0%2.2%4/9
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
Median of the sector 27 symbols 44.6B USD +9.4%67.2%17.8%13.2%13.6%38.4%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector CNC next to ELV – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+11.9% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 11.9% per year on average – at least as fast as the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−3.4% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 3.43 USD. Five years ago the margin was 1.6%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.70 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.70 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
194.8B USD
Revenue vs. prior year
+19.4%
Net income (FY)
−6.7B USD
Net income vs. prior year
−301.9%
EPS (FY)
-13.53 USD
Superinvestors holding
4 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 17, 2026 · Balance sheet Sep 30, 2026 (filed Oct 27, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 194.8B−6.7B −3.4% −13.53 – –
2024Dec 31, 2024 163.1B3.3B 2.0% 6.31 – –
2023Dec 31, 2023 154.0B2.7B 1.8% 4.95 – –
2022Dec 31, 2022 144.5B1.2B 0.8% 2.07 – –
2021Dec 31, 2021 126.0B1.3B 1.1% 2.28 – –
2020Dec 31, 2020 111.1B1.8B 1.6% 3.12 – –
2019Dec 31, 2019 74.6B1.3B 1.8% 3.14 – –
2018Dec 31, 2018 60.1B900.0M 1.5% 2.26 – –
2017Dec 31, 2017 48.4B828.0M 1.7% 2.35 – –
2016Dec 31, 2016 40.6B562.0M 1.4% 1.72 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 50.6B−71.0M −0.1% −0.14 – –
Q2/26Jun 30, 2026 53.6B1.1B 2.0% 2.19 – –
Q1/26Mar 31, 2026 49.9B1.5B 3.1% 3.11 – –
Q4/25*Dec 31, 2025 49.7B−1.1B −2.2% – – –
Q3/25Sep 30, 2025 49.7B−6.6B −13.3% −13.50 – –
Q2/25Jun 30, 2025 48.7B−253.0M −0.5% −0.51 – –
Q1/25Mar 31, 2025 46.6B1.3B 2.8% 2.63 – –
Q4/24*Dec 31, 2024 40.8B283.0M 0.7% – – –
Q3/24Sep 30, 2024 42.0B713.0M 1.7% 1.36 – –
Q2/24Jun 30, 2024 39.8B1.1B 2.9% 2.16 – –
Q1/24Mar 31, 2024 40.4B1.2B 2.9% 2.16 – –
Q4/23*Dec 31, 2023 39.5B45.0M 0.1% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Per-share values adjusted for stock split 2:1 (between Oct 23, 2018 and Feb 19, 2019). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $3.8M1 person −$3.8M
6 months $00 people $12.1M2 people −$12.1M
12 months $00 people $14.6M2 people −$14.6M

Latest transactions

  • Aug 26, 2026 Koster Christopher Officer Open-market sale 56,500 shares · $3.8M · SEC
  • Aug 18, 2026 Koster Christopher Officer Open-market sale 47,603 shares · $3.1M · SEC
  • Jun 10, 2026 Burdick Kenneth A Director Open-market sale 80,000 shares · $5.2M · SEC
  • Dec 4, 2025 Burdick Kenneth A Director Open-market sale 32,796 shares · $1.3M · SEC
  • Dec 3, 2025 Burdick Kenneth A Director Open-market sale 33,211 shares · $1.3M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Centene Corporation?

All superinvestor portfolios

4 of 26 tracked superinvestors report a position.

Superinvestors with a position in Centene Corporation, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
David Einhorn Greenlight Capital 2.9% unchanged Q3 2026
Bridgewater Associates 0.4% +236.2% increased Q3 2026
Renaissance Technologies 0.3% +79.1% increased Q3 2026
Steve Cohen Point72 Asset Management 0.2% +112.6% increased Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on CNC yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: CNC

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close